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MiR-1, miR-133a, and miR-206 are abundantly expressed in skeletal muscle and regulate the 
post-transcriptional expression of target genes. These miRNAs are upregulated in sera of DMD, BMD, LGMD, 
and FSHD patients, as well as mdx mice and CXMDj dogs, suggesting that the serum miRNAs may substitute for 
CK levels as be novel biomarkers for muscle disorders. These miRNAs are released into the extracellular 
environment in vesicular structures called exosomes, by mechanisms that are regulated by calcium, oxidative 
stress, and NO signaling. In this review, we will highlight the relationship between calcium, oxidative stress, and 
NO signaling and the release of miRNAs via exosomes as well as discuss the functions of these miRNAs. 
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Introduction 
miRNAs are evolutionally conserved non-coding single 
strand RNAs of approximately 19 - 23 nucleotides that 
regulate post-transcriptionally gene expression by binding to 
the 5’- or 3’-untranslated regions of target mRNAs [1,2] and 
thereby controlling their translation and/or mRNA 
degradation [3]. A single miRNA targets the expression of 
multiple genes, whereas one gene is regulated by multiple 
miRNAs [4]. The miRNAs miR-1 and miR-133a are 
expressed in cardiac and skeletal muscle, whereas 
miR-206/miR-133b is expressed only in skeletal muscle [5, 6]. 
The upregulation of miR-1, miR-133, and miR-206 levels 
during myoblast differentiation is known to protect myocytes 
against atrophy [7]. The expression of miR-1 is inhibited by 
the mTOR-specific inhibitor rapamycin and regulates 
myocyte fusion through the suppression of HDAC4 during 
myoblast differentiation in vitro and skeletal muscle 
regeneration in vivo [8]. MiR-1, miR-133, and miR-206 are 
upregulated in sera of DMD patients, mdx mice, and CXMDj 
dogs [9]. However, miR-1 and miR-133a expression is 
significantly downregulated by approximately two-fold in 
muscle tissue of mdx mice, whereas miR-206 is significantly 
upregulated [10]. Because the level of these miRNAs are less 
affected by exercise compared with creatine kinase levels, 
and furthermore they correlate with the level of motor 
activity of DMD patients [11], these miRNAs have been 
suggested as novel stable biomarkers for the diagnosis of and 
the outcomes of potential therapies for DMD. Moreover, as 
these miRNAs are upregulated in sera of BMD, LGMD, and 
FSHD patients [12], they have a potential as new biomarkers 
for muscle diseases. 
MiRNAs release 
In general, miRNAs are located in the intracellular- or 
extracellular space, depending on their consensus motif [13]. 
MiRNAs are released into the circulating blood encapsulated 
in exosomes, which are small membrane vesicles 
(approximately 100 nm in diameter) of late endosome origin 
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that are formed in the MVB, or are complexed with 
RNA-binding proteins, such as argonaute 2, high-density 
lipoprotein, and nucleophosmin 1, to protect their 
degradations by RNases [14-16]. Exosomes transport mRNAs, 
miRNAs, and proteins into target cells by their fusion and 
internalization by endocytosis into the target cells. The 
secretion of exosomes is induced by ceramide formation, 
which triggers the budding of intraluminal vesicles into the 
MVB [17, 18] and Rab GTPase family proteins regulate the 
budding, transport, motility, docking, and fusion of vesicles 
from the trans-Golgi network to the plasma membrane in a 
calcium-dependent manner [19-21]. 
Ca2+ signaling and miRNAs in muscle disorders 
Ca2+ influx from the extracellular compartment or 
increase in cytosolic Ca2+ in DMD patients are induced by 
membrane instability caused by the disruption of DGC in 
their muscles of DMD, leading to a worsening of their 
dystrophic phenotypes [22-26]. The main intracellular Ca2+ 
reservoir in mammalian cells is the ER, which contains three 
types of proteins that regulate intracellular Ca2+ 
concentration in the lumen, namely, 1) Ca2+ pumps that 
promote Ca2+ uptake, 2) Ca2+ -binding proteins that enable 
the store of Ca2+ in the ER lumen, and 3) Ca2+ channels that 
enable the release of Ca2+ into the cytosol [27]. IP3Rs are Ca2+ 
channels that are activated by the IP3-producing enzyme 
PLC, which leads to IP3-induced Ca2+ release [28-30]. In 
normal muscle, type I and II IP3Rs (IP3RI and IP3RII) are 
abundantly expressed in type II fibers, whereas the type III 
IP3R (IP3RIII) is distributed uniformly through muscles [31]. 
IP3RII protein level are significantly increased by 
approximately five fold in a DMD-derived muscle cell line, 
in which the slow Ca2+ signal activated through PLC that is 
induced by electrical stimulation was significantly faster than 
that in a control cell line [31]. IP3RII expression, which is 
indispensable in the heart but dispensable in skeletal muscle, 
is suppressed by miR-133a via SRF in both cardiac and 
skeletal muscle [32] and is suppressed in myocytes by 
alterations in the interaction or activity of SRF cofactors 
through IP3-induced calcium release [33]. 
Exosomal miRNAs 
C2C12 myoblasts and myotubes were reported to secrete 
0.37±0.15 and 0.41±0.23 g/mL/24 hr of exosomes into the 
medium, respectively [34]. Levels of miR-1, miR-133a, and 
miR-206 were reported to be upregulated in exosomes from 
C2C12 myotubes compared with those from myoblasts [34]. 
Exosomal miRNAs released from myotubes were found to 
repress Sirt1 gene expression in myoblasts [34]. In addition, 
exosomes from myotubes were found to reduce the 
proliferation of myoblasts and to induce their differentiation 
via the downregulation of Cyclin D1 and the upregulation of 
myogenin [34]. Larger amounts of muscle-enriched miRNAs 
in both exosomal and exosome-depleted supernatant 
fractions were detected in the serum of DMD patients 
compared with that in the controls [12]. Moreover, serum 
miR-133a levels in DMD patients were significantly 
increased in the exosomal fraction compared with the 
exosome-depleted supernatant fraction [12]. 
NO signaling and miRNAs in muscle diseases 
The dysregulation of the levels of miRNAs cause 
abnormal muscle homeostasis, resulting in muscle diseases 
[35-37]. DMD [OMIM 310200] is an X-linked recessive 
progressive muscle disease with a prevalence of 1 in 3,500 
live male births, and is caused by mutations in the dystrophin 
gene [3]. The dystrophin protein forms the DGC that 
integrates nNOS at sarcolemma, and produces NO, which 
inhibits the activity of HDAC2, a transcriptional repressor 
that acts via S-nitrosylation [38], which subsequently activates 
miR-1 and miR-133a [10]. The absence of dystrophin in DMD 
patients decreases the transcription of miR-1 and miR-133a 
by the binding of HDAC2 to their promoters in a 
NO-dependent manner [10]. On the other hand, miR-206 is 
upregulated in dystrophic muscle in a 
Dys/nNOS-independent pathway. The increase in miR-206 
level may be important for the differentiation of satellite cells 
through the repression of Pax7 expression, because miR-206 
is present in immature regenerating and differentiated muscle 
in mdx mice [39]. Such abnormal expression of these mRNAs 
in mdx mice return to normal levels similar to those of 
wild-type mice by dystrophin rescue [10]. In mdx mice and 
DMD patient muscle, the miR-1 and miR-206 levels are 
significantly downegulated and upregulated, respectively [40]. 
Such dysregulated miRNA levels are restored to those of 
wild-type mice by class I HDAC inhibition and eNOS 
expression [40]. 
MiRNAs in myoblast proliferation and differentiation 
The expression levels of miR-1 and miR-133a are 
upregulated in differentiated C2C12 myoblasts and myotubes 
[5]. Both miR-1 and miR-133a play roles in the in vitro 
differentiation and proliferation of myoblasts through the 
repressions of HDAC4 and SRF, respectively, in 
differentiation medium [5]. On the other hand, miR-133a 
represses myoblast proliferation and promotes the 
differentiation of myoblasts into myotubes by inhibition of 
the ERK1/2 pathway through direct silencing of FGFR1 and 
PP2AC genes, in growth medium [41]. Furthermore, 
miR-133a expression is repressed by ERK1/2 activation, and 
moreover, miR-133a is involved in a feedback circuit 
regulating the ERK1/2 pathway, which controls myoblast 
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proliferation and differentiation [41]. In addition, the 
expression of miR-133a inhibits the proliferation of C2C12 
myoblasts and promotes their differentiation at an early stage 
in the differentiation process, through direct suppression of 
translation of the UCP2 gene, a regulator of energy 
expenditure and thermogenesis [42], or the production of 
muscle-specific transcripts by targeting alternative splicing 
factor, nPTB [43]. The levels of miR-1, miR-133, and 
miR-206 are upregulated during muscle regeneration in mice 
after muscle injury [39,12] Mice lacking miR-133a show 
centronuclear myopathy in type II fast-twitch myofibers, 
accompanied by impaired fast-to-slow myofiber conversion, 
increased oxidative enzyme activity, and increased 
expression of the miR-133a target gene, dynamin2, which is 
a large GTPase implicated in the regulation of actin and 
microtubule cytoskeletons [44]. Recently, it was reported that 
miR-133a promotes slow-to-fast myofiber conversion 
through the indirect downregulation of MyHC-I gene 
expression, via the inhibition of the TEAD1 transcriptional 
factor by thyroid hormone signaling [45]. 
Although a low-dose of the synthetic glucocorticoid DEX 
protects muscle cells from atrophy through the suppressions 
of pro-inflammatory cytokines, high doses of DEX induce 
muscle atrophy by the inhibition of IGF-I signaling through a 
decrease of PI3K activity [46-50]. The expression of IGF-IR is 
directly suppressed by miR-133a, which leads to the 
inhibition of PI3K/Akt signaling by a negative feedback loop 
[51]. The long non-coding pre-RNA, linc-MD1, which 
enhances miR-133 function by acting as a ceRNA via 
binding to it and hence inhibiting HuR expression, controls 
the early phases of myogenesis [52]. In addition, the 
overexpression of the miR-133a in the presence of the 
reprogramming factors, Gata4, Mef2c, and Tbx5, leads to the 
efficient generation of beating iCMs, via the direct repression 
Snai1, a master regulator of epithelial-to-mesenchymal 
transition [53]. 
Muscle disorders associated dysregulated exosome 
secretion 
Exosomes carrying miRNAs are secreted by activation of 
the Ca2+ signal pathway, which regulates the docking and 
fusion of MVBs into the plasma membrane through SNAREs 
[19, 20, 54-56], or S1P/ceramide pathway [17, 57-59], in which the 
ceramide synthesis enzyme, Smpd3, is activated by oxidative 
stress [60-63], resulting in the secretion of exosomes [64]. The 
absence of dystrophin in mdx mice induces an abnormal 
increase of calcium influx in the sarcolemma of adult skeletal 
muscle fibers, resulting in muscle degeneration [65-69]. In 
addition, the loss of dystrophin inhibits NO signaling by 
preventing the associations of the DGC with nNOS, which 
contributes to the muscle atrophy [70-74]. The eNOS pathway 
negatively regulates the secretion of exosomes [75]; thus, an 
increase of exosome secretion into the serum from muscle 
tissue in DMD patients might be caused by calcium, 
oxidative stress, or NO signaling. FSHD (OMIM158900) is 
an autosomal-dominant neuromuscular disorder with a 
prevalence of approximately one per 20,000 in the Japanese 
population [76], is caused by a loss of a stretch of 
microsatellite repeats approximately 3.3 kb in length in the 
D4Z4 on chromosome 4q35 [77], which contains a functional 
promoter for DUX4 and DUX4c [78, 79] This muscle disorder 
is characterized by the overexpressions of DUX4 and 
DUX4c in the muscle, which induces the expressions of 
miR-1, miR-133a, and miR-206 [80]. Myoblasts from FSHD 
patients show increased susceptibility to oxidative stress 
[81-83], which enhances the release of exosomes [64]. LGMD is 
caused by one of a total of 22 autosomal dominant or 
recessive gene mutations, and has an incidence of about one 
per 20,000 individuals [84]. Of the various types, LGMD2A is 
caused by a mutation in the enzyme calpain 3, resulting in 
increased oxidative stress in the muscles of patients with this 
disease [85]. Therefore, oxidative stress in the muscles of 
FSHD and LGMD2A patients might regulate the secretion of 
exosomes into the extracellular environment. 
Conclusions 
Increasing lines of evidence indicate that miRNAs that are 
abundant in the muscle play pivotal roles in the regulations 
of myogenesis, and are associated with muscle disorders. The 
secretion of miRNA-containing exosomes is regulated by the 
calcium, oxidative stress, and NO signaling pathways, which 
are all dysregulated in muscle disorders. Exosomes secreted 
into the extracellular space can communicate with target cells 
through the transfer of miRNAs. Therefore, not only the 
miRNAs, but also the exosomes are potential targets for new 
diagnostic tools and novel therapies for muscle disorders. 
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